[18F]Florbetaben PET Imaging for Alzheimer's Disease in China

Open-label, single-arm trial of florbetaben in Alzheimer's disease (AD), sponsored by Sinotau Pharmaceutical Group. Primary endpoints: Verify the safety of subjects after a single intravenous administration of 18FBB up to 4 weeks and Evaluation of the ability of qualitative readings of PET imaging to distinguish non-cognitively impaired subjects from mild to moderate AD subjects up to 4 weeks. Started Jan 2021; status: completed.